tiprankstipranks
Acrivon Therapeutics to presents data on deployment of AP3 platform
PremiumThe FlyAcrivon Therapeutics to presents data on deployment of AP3 platform
4M ago
Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline
Premium
Company Announcements
Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline
5M ago
Acrivon announces initial patient dosing in Phase 1 trial of ACR-2316
Premium
The Fly
Acrivon announces initial patient dosing in Phase 1 trial of ACR-2316
5M ago
Acrivon reports data from ongoing ACR-368 registrational intent Phase 2 study
PremiumThe FlyAcrivon reports data from ongoing ACR-368 registrational intent Phase 2 study
6M ago
Acrivon Therapeutics to host investor event on Phase 2 data of ACR-368
Premium
The Fly
Acrivon Therapeutics to host investor event on Phase 2 data of ACR-368
6M ago
Acrivon Therapeutics price target lowered to $18 from $21 at Oppenheimer
Premium
The Fly
Acrivon Therapeutics price target lowered to $18 from $21 at Oppenheimer
7M ago
Acrivon Therapeutics reports Q1 EPS (73c), consensus (84c)
PremiumThe FlyAcrivon Therapeutics reports Q1 EPS (73c), consensus (84c)
10M ago
Acrivon Therapeutics downgraded to Neutral from Buy at Ladenburg
Premium
The Fly
Acrivon Therapeutics downgraded to Neutral from Buy at Ladenburg
10M ago
Acrivon Therapeutics price target raised to $25 from $18 at BMO Capital
Premium
The Fly
Acrivon Therapeutics price target raised to $25 from $18 at BMO Capital
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100